Why the study?
Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
Does icosapent ethyl 2 g twice daily reduce ischemic events in patients with elevated triglyceride levels despite the use of statins?
Icosapent ethyl significantly reduces the risk of ischemic events in statin-treated patients with elevated triglycerides.
Answers are grounded in this paper and cite their sources.
Supports icosapent ethyl addition in statin-treated patients with elevated triglycerides; confirms ischemic event reduction in this population.
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: